American Journal of Ophthalmology
Volume 148, Issue 2 , Pages 221-226 , August 2009

Assessing the Efficacy of Latanoprost vs Timolol Using an Alternate Efficacy Parameter: The Intervisit Intraocular Pressure Range

  • Rohit Varma

      Affiliations

    • Keck School of Medicine, University of Southern California, Los Angeles, California
    • Corresponding Author InformationInquiries to Rohit Varma, Doheny Eye Institute and the Department of Ophthalmology, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, DEI-4900, Los Angeles, CA 90033
    • ,
  • Lie-Ju Hwang

      Affiliations

    • Pfizer Inc, New York, New York
    • ,
  • John W. Grunden

      Affiliations

    • Pfizer Inc, New York, New York
    • ,
  • Gerald W. Bean

      Affiliations

    • Independent Consultant, Burkett, Texas
    • ,
  • Marla B. Sultan

      Affiliations

    • Pfizer Inc, New York, New York
    • New York Eye and Ear Infirmary, New York, New York

,Accepted 21 February 2009.

References 

  1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7 (The relationship between control of intraocular pressure and visual field deterioration). Am J Ophthalmol. 2000;130:429–440
  2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505
  3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279
  4. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56
  5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713
  6. Bergeå B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997–1004
  7. Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology. 2008;115:1123–1129
  8. Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch Ophthalmol. 2007;125:1010–1013
  9. O'Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111:491–500
  10. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:274–279
  11. Orzalesi N, Fogagnolo P, Rossetti L. Intraocular pressure fluctuations in glaucoma. Arch Ophthalmol. 2008;126:745
  12. Weinreb RN, Liu JH. Nocturnal rhythms of intraocular pressure. Arch Ophthalmol. 2006;124:269–270
  13. Varma R, Hwang LJ, Grunden JW, Bean GW. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol. 2008;145:336–342
  14. Parrish RK, Palmberg P, Sheu WP XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703
  15. Camras CB United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a 6-month masked, multicenter trial in the United States. Ophthalmology. 1996;103:138–147
  16. Watson P, Stjernschantz J Latanoprost Study Group. A 6-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126–137
  17. Alm A, Stjernschantz J Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning (A comparison with timolol). Ophthalmology. 1995;102:1743–1752
  18. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, 6-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104
  19. Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2005;243:513–518
  20. Saccá SC, Rolando M, Marletta A, et al. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma, and normal subjects. Ophthalmologica. 1998;212:115–119
  21. Bengtsson B, Leske MC, Hyman L Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114:205–209
  22. Forsman E, Kivelä T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma. 2007;16:313–319
  23. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627–1635
  24. Simmons ST, Bernstein P, Hollander DA. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Am J Ophthalmol. 2008;146:473–477
  25. Javitt JC, McBean AM, Nicholson GA, Babish JD, Warren JL, Krakauer H. Undertreatment of glaucoma among Black Americans. N Engl J Med. 1991;325:1418–1422
  26. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991;325:1412–1417
  27. Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138:S19–S31
  28. Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122:813–820
  29. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma (The Baltimore Eye Survey). JAMA. 1991;266:369–374
  30. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 3 (Baseline characteristics of black and white patients). Ophthalmology. 1998;105:1137–1145

 See accompanying Editorial on page 177.

PII: S0002-9394(09)00166-4

doi: 10.1016/j.ajo.2009.02.035

American Journal of Ophthalmology
Volume 148, Issue 2 , Pages 221-226 , August 2009

Article Tools

* Image Usage & Resolution